Evidence map›Paper›PMID 41772289›Full record

ReviewJournal of hematopathology2026

A rare diffuse follicular lymphoma with TP53 mutation and copy-neutral loss of heterozygosity at 1p36: insights into diagnosis, disease progression, and literature review.

Mitra Abdolahi, Phassawan Rungsiprakarn, Ahmed Lazim, Pei Jianming, Nicholas Mackrides, Reza Nejati

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Journal of hematopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mitra AbdolahiDepartment of Pathology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, 19111, USA.
Phassawan RungsiprakarnDepartment of Pathology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, 19111, USA.
Ahmed LazimDepartment of Pathology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, 19111, USA.
Pei JianmingClinical Genomics Laboratory, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, 19111, USA.
Nicholas MackridesDepartment of Pathology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, 19111, USA.
Reza NejatiDepartment of Pathology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, 19111, USA. Reza.Nejati@fccc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFollicular lymphoma (FL) is a common type of non-Hodgkin lymphoma typically characterized by a nodular growth pattern and the t(14;18) translocation. A rare variant, FL with a predominantly diffuse growth pattern (dFL), lacks this translocation, demonstrates diffuse architecture, and is frequently associated with deletion of 1p36. CASE PRESENTATION: We report the case of a 43-year-old man who presented with an inguinal mass and was diagnosed with follicular lymphoma showing a predominantly diffuse pattern. Fluorescence in situ hybridization (FISH) analysis was negative for both BCL2 rearrangement and TNFRSF14 (1p36) deletion. Chromosomal microarray (CMA) and next-generation sequencing (NGS) were subsequently performed for further molecular characterization.

resultsCMA revealed copy-neutral loss of heterozygosity (cnLOH) at 1p36 and additional abnormalities involving 16p that were not detectable by FISH. NGS identified a TP53 mutation, a finding not previously reported in dFL and typically associated with more aggressive lymphoma behavior. Although dFL is generally considered an indolent and localized disease, the patient developed axillary recurrence within 1 year, requiring radiation therapy.

conclusionThese findings underscore the importance of comprehensive molecular testing, such as NGS and CMA, to refine prognostic assessment and guide personalized treatment strategies for this rare lymphoma variant.

Indexed as

Chromosomes, Human, Pair 1Loss of HeterozygosityLymphoma, FollicularMutationTumor Suppressor Protein p53AdultDisease ProgressionHumansIn Situ Hybridization, FluorescenceMaleTP53 protein, humanTumor Suppressor Protein p531p36Copy-neutral loss of heterozygosityDiffuse follicular lymphomaTP53 mutation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.